Diabetic Peripheral Neuropathy (DPN) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033 thelansis.com

Diabetic peripheral neuropathy (DPN) is a common and chronic complication of diabetes, leading to distressing and expensive clinical issues such as foot ulcers, leg amputations, and neuropathic pain (painful DPN). This condition is linked to increased mortality and mainly results in diabetic foot ulcers and neuropathic pain. Typically, DPN is the most prevalent form of neuropathy in diabetes, affecting both sensory and motor nerves in a peripheral distribution. However, individuals’ impact on small and large sensory and motor fibers varies. DPN’s most significant risk factors are the duration of diabetes and glycemic control. Additional risk factors for cardiovascular disease, such as obesity, hypertension, smoking, and dyslipidemia, are also associated with DPN. The pathogenesis of DPN is complex and not fully understood. DPN risk is low at the diagnosis of type 1 diabetes, so foot screening should begin five years after diagnosis. Limited treatments are available to reverse the underlying nerve damage that causes DPN. Therefore, preventing DPN is a crucial aspect of diabetes care, and the American Diabetes Association (ADA) recommends achieving optimal glucose control in both type 1 and type 2 diabetes to prevent or slow the progression of DPN.
• In the general US population aged 40 years or older, the overall prevalence of peripheral neuropathy (PN) defined by monofilament insensitivity was 13.5% in 2010, which equated to 18.6 million US adults.
• Among adults aged 40 or older, the prevalence of PN was 28.4% in individuals with diabetes (4.2 million) and 11.8% in those without diabetes (14.4 million).

Thelansis’s “Diabetic Peripheral Neuropathy (DPN) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033″ covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Diabetic Peripheral Neuropathy (DPN) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Diabetic Peripheral Neuropathy (DPN) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Diabetic Peripheral Neuropathy (DPN) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Diabetic Peripheral Neuropathy (DPN) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033